Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery

Journal of Surgical Oncology

Volumn 105, Issue 4, 2012, Pages 342-350

  Saxena, Akshat ^a   Chua, Terence C ^a   Zhao, Jing ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

carcinoid; cryoablation; hepatectomy; hepatic metastases; neuroendocrine neoplasm; recurrence; survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOISOTOPE; RECOMBINANT ALPHA INTERFERON; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CRYOABLATION; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HISTOLOGY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; NEUROENDOCRINE NEOPLASM HEPATIC METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; SUBPHRENIC ABSCESS; TUMOR LOCALIZATION; TUMOR VOLUME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SECOND-LOOK SURGERY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84857058953     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22114     Document Type: Article

References (28)

1. Yao JC, Hassan M, Phan A, et al.: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Chamberlain RS, Canes D, Brown KT, et al.: Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445. (Pubitemid 30181109)
3. Modlin IM, Lye KD, Kidd M,: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959. (Pubitemid 36173145)
4. Quaedvlieg PF, Visser O, Lamers CB, et al.: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001; 12: 1295-1300. (Pubitemid 32994760)
5. Mayo SC, de Jong MC, Pulitano C, et al.: Surgical management of hepatic neuroendocrine tumor metastasis: Results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17: 3129-3136.
6. Frilling A, Li J, Malamutmann E, et al.: Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96: 175-184.
7. Schurr PG, Strate T, Rese K, et al.: Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg 2007; 245: 273-281. (Pubitemid 46148487)
8. Cho CS, Labow DM, Tang L, et al.: Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008; 113: 126-134. (Pubitemid 351976393)
9. Rinke A, Muller HH, Schade-Brittinger C, et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
10. Saxena A, Chua TC, Bester L, et al.: Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases. Ann Surg 2010; 251: 910-916.
11. Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
12. Rhee TK, Lewandowski RJ, Liu DM, et al.: 90Y Radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg 2008; 247: 1029-1035. (Pubitemid 351770424)
13. Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005; 104: 1590-1602. (Pubitemid 41437421)
14. Eriksson BK, Larsson EG, Skogseid BM, et al.: Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83: 2293-2301. (Pubitemid 28533498)
15. Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
16. Plockinger U, Rindi G, Arnold R, et al.: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
17. Sarmiento JM, Heywood G, Rubin J, et al.: Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37. (Pubitemid 36759176)
18. Chua TC, Saxena A, Chu F, et al.: Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients-experience from an Australian hepatobiliary unit. J Gastrointest Surg 2010; 14: 1370-1380.
19. Yan TD, Padang R, Morris DL,: Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: Longterm survival can be achieved in patients with multiple bilateral liver metastases. J Am Coll Surg 2006; 202: 100-111. (Pubitemid 41831480)
20. Moertel CG,: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522.
21. Janson ET, Holmberg L, Stridsberg M, et al.: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8: 685-690. (Pubitemid 27372168)
22. Arnold R, Rinke A, Schmidt C, et al.: Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Pract Res Clin Gastroenterol 2005; 19: 649-656.
23. Sutcliffe R, Maguire D, Ramage J, et al.: Management of neuroendocrine liver metastases. Am J Surg 2004; 187: 39-46. (Pubitemid 38045501)
24. O'Toole D, Hentic O, Corcos O, et al.: Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80: 79-84. (Pubitemid 39382375)
25. Gillams A, Cassoni A, Conway G, et al.: Radiofrequency ablation of neuroendocrine liver metastases: The Middlesex experience. Abdom Imaging 2005; 30: 435-441. (Pubitemid 41176121)
26. Reddy SK, Clary BM,: Neuroendocrine liver metastases. Surg Clin North Am 2010; 90: 853-861.
27. Mazzaglia PJ, Berber E, Milas M, et al.: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19. (Pubitemid 47042092)
28. Elvin A, Skogseid B, Hellman P,: Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging 2005; 30: 427-434. (Pubitemid 41176120)